Introduction: Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer in adults and presents variable clinical behavior, with risks of late recurrence and metastasis. The PIK3CA gene, which encodes the p110? subunit of PI3K, is involved in signaling pathways related to cell proliferation and survival, and is frequently altered in cancers. In ccRCC, PIK3CA is not listed among genes with known prognostic value, making its analysis relevant to investigate its potential as a prognostic biomarker. Objectives: To analyze the expression of the PIK3CA gene in clear cell renal cell carcinoma (ccRCC) and its association with patient overall survival (OS), based on bioinformatic data from public databases. Methods: This is an observational, descriptive, and exploratory study based on bioinformatic analysis of public databases. PIK3CA gene expression and its association with OS and DFS were evaluated using the Gene Expression Profiling Interactive Analysis 2 (GEPIA2) platform, based on Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) data. Survival analysis was performed using Kaplan–Meier curves, with statistical comparison by log-rank test, as provided by the GEPIA2 platform. Protein expression was assessed through the Human Protein Atlas (HPA), based on immunohistochemistry data available using the antibody HPA009985, including analysis of staining intensity, proportion of positive tumor cells, and subcellular localization in renal tumor tissues. Results: Gene expression analysis in GEPIA2 revealed that the PIK3CA gene exhibits significantly higher expression in the tumor tissues of ccRCC compared to normal tissues (n=523 vs. n=100). In overall survival (OS) analysis, patients with high PIK3CA expression had a better prognosis (HR=0.58; p=0.00066), with a statistically significant difference (Log-rank p=0.00056; n=257 for high expression and n=258 for low expression). In DFS (although a trend towards better survival was observed for patients with high expression (HR=0.72; p=0.078), this difference was not statistically significant (Log-rank p=0.075). The analysis of PIK3CA protein expression in ccRCC, revealed that among 12 samples evaluated, 5 (41.7%) showed medium expression, 2 (16.7%) low expression, and none showed high expression, while 5 samples (41.7%) exhibited no detectable protein expression. Regarding staining intensity, 5 samples (41.7%) showed moderate staining, 3 (25%) weak staining, and 4 (33.3%) were negative. As for the proportion of positively stained tumor cells, 3 samples (25%) had over 75% positive cells, 4 (33.3%) showed positivity in 25%–75% of cells, 1 (8.3%) had less than 25% positivity, and 4 (33.3%) showed no positive staining. In terms of subcellular localization, 8 of the 12 samples (66.7%) exhibited a cytoplasmic and/or membranous staining pattern, while 4 (33.3%) had no detectable staining; nuclear staining was not observed. Conclusion: The results demonstrate that the PIK3CA gene is overexpressed in tumor tissues of ccRCC and is associated with better overall survival outcomes, suggesting a potential prognostic role. However, the analysis of protein expression revealed heterogeneous and partially undetectable protein levels, which may reflect post-transcriptional regulatory mechanisms or methodological limitations of immunohistochemistry. Therefore, although the findings indicate the potential of PIK3CA as a prognostic biomarker in ccRCC, further studies are needed to validate its clinical applicability.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
